author-photo

Katherine McNamara

Stanford University

11

Papers

497

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response

2021
Show All
- Source
- Cite
- Save
Citations (6)
Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing

2020 eLife
Show All
- Source
- Cite
- Save
Citations (18)
Author response: Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing

2020 eLife
Show All
- Source
- Cite
- Save
Citations (0)
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

2020 medRxiv
Show All
- Source
- Cite
- Save
Citations (1)
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).

2020 Nature Communications
Show All
- Source
- Cite
- Save
Citations (12)
Abstract P4-07-01: Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

2019 Nature Communications
Show All
- Source
- Cite
- Save
Citations (25)
Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

2019 Nature Communications
Show All
- Source
- Cite
- Save
Citations (0)
Clonal replacement of tumor-specific T cells following PD-1 blockade

2019 bioRxiv
Show All
- Source
- Cite
- Save
Citations (3)